权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

NCTN Deep South Research Consortium

NCTN 深南研究联盟

基本信息

批准号：
10361237
负责人：
MARY-ANN BJORNSTI
金额：
$ 48.24万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-03-06 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10361237
关键词：
Achievement Address Alabama American College of Radiology Imaging Network Area Arkansas Basic Science Cancer Biology Cancer Control Cancer Patient Cancer and Leukemia Group B Clinical Cancer Center Clinical Investigator Clinical Research Clinical Trials Clinical Trials Cooperative Group Clinical Trials Network Communities Community Outreach Comprehensive Cancer Center Cooperative Group Program Country Deep South Detection Diagnosis Doctor of Medicine Doctor of Philosophy Eastern Cooperative Oncology Group Enrollment Ensure Faculty Fostering Funding Gynecologic Oncology Group Health Disparities Research Home Hospitals Infrastructure Intention International Intervention Investigational Therapies Knowledge Lead Leadership Louisiana Malignant Neoplasms Mentors Minority Minority Participation Mississippi Names National Clinical Trials Network National Surgical Adjuvant Breast and Bowel Project Outcome Patients Persons Phase Physicians Process Quality of life Radiation Therapy Oncology Group Recording of previous events Research Research Personnel Role Scientist Site Socioeconomic Status Southwest Oncology Group Training Training Programs Training and Infrastructure Translating Translational Research United States Universities Vision Work anticancer research cancer care cancer clinical trial cancer health disparity cancer prevention cancer risk clinical trial participant demographics ethnic minority interest member minority health disparity minority scientist next generation organizational structure patient population population based programs racial health disparity recruit survivorship translational scientist treatment trial

项目摘要

The University of Alabama at Birmingham Comprehensive Cancer Center (UAB CCC) has a long history of participation within the nation's cancer related Clinical Trials Cooperative Group Program. Specifically, UAB was a founding member of the GOG, and has been a member of RTOG, ECOG, ACRIN. CALGB, NSABP, and SWOG. UAB CCC is a current member of the ALLIANCE, ECOG-ACRIN, NRG and SWOG cooperative groups. The UAB NCTN Deep South Research Consortium (DSRC) is currently a Lead Academic Participating Site in the NCI's National Clinical Trials Network (NCTN) Program, and now submits this proposal to continue to serve the NCI in this capacity. It is our intention to continue as a leading contributor of scientific leaders and clinical trial participants to the NCTN Program in the U.S. and particularly in the Southeast. To accomplish this overall vision, we propose the following specific aims: 1) To further enhance the involvement of existing UAB CCC scientific leadership in NCTN Cooperative Group related clinical and translational research and to develop the next generation of NCTN Cooperative group scientific leaders within the UAB CCC, and 2) To further refine a clinical trials process within the DSRC that optimizes accrual of potentially eligible cancer patients and patients at risk for cancer to NCTN Cooperative Group clinical trials, and 3) To further increase minority accrual to NCTN Cooperative Group trials. We include in this proposal a detailed description of our DSRC cooperative group scientific and patient accrual contributions and accomplishments, a leadership and organizational structure for our Consortium, and how we intend to utilize existing DSRC infrastructure to achieve our aims. Further, we also include a detailed description of our Junior Investigator Recruitment and Mentoring Program.

阿拉巴马大学伯明翰综合癌症中心 (UAB CCC) 拥有悠久的历史参与国家癌症相关临床试验合作组的历史程序。具体来说，UAB 是 GOG 的创始成员，并且一直是 RTOG、ECOG、ACRIN。 CALGB、NSABP 和 SWOG。 UAB CCC 是该协会的现任成员 ALLIANCE、ECOG-ACRIN、NRG 和 SWOG 合作团体。 UAB NCTN 深南研究联盟 (DSRC) 目前是 NCI 的主要学术参与网站国家临床试验网络 (NCTN) 计划，现提交此提案以继续以此身份为 NCI 服务。我们打算继续作为科学领域的主要贡献者美国尤其是美国 NCTN 项目的领导者和临床试验参与者东南。为实现这一总体愿景，我们提出以下具体目标： 1) 进一步加强现有 UAB CCC 科学领导层对 NCTN 合作小组的参与相关临床和转化研究并开发下一代 NCTN UAB CCC 内的合作小组科学领导者，以及 2) 进一步完善临床试验 DSRC 内优化潜在合格癌症患者和患者应计的流程有癌症风险参加 NCTN 合作组临床试验，以及 3) 进一步增加少数群体 NCTN 合作组试验的应计费用。我们在此提案中详细描述了我们的 DSRC 合作小组科学和患者应计贡献和成就，我们联盟的领导和组织结构，以及我们打算如何利用现有的 DSRC 基础设施可实现我们的目标。此外，我们还详细描述了我们的初级研究员招募和指导计划。